Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue: 2020-2025

Historic Non-Current Deffered Revenue for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $193.1 million.

  • Foghorn Therapeutics' Non-Current Deffered Revenue fell 22.62% to $193.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.1 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $234.5 million for FY2024, which is 12.55% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non-Current Deffered Revenue of $193.1 million as of Q3 2025, which was down 6.64% from $206.8 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Non-Current Deffered Revenue peaked at $322.7 million during Q4 2021, and registered a low of $11.9 million during Q1 2021.
  • Over the past 3 years, Foghorn Therapeutics' median Non-Current Deffered Revenue value was $259.5 million (recorded in 2024), while the average stood at $251.9 million.
  • Per our database at Business Quant, Foghorn Therapeutics' Non-Current Deffered Revenue skyrocketed by 2,569.37% in 2022 and then declined by 22.62% in 2025.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Non-Current Deffered Revenue stood at $322.7 million in 2021, then declined by 5.80% to $304.0 million in 2022, then dropped by 11.80% to $268.1 million in 2023, then declined by 12.55% to $234.5 million in 2024, then declined by 22.62% to $193.1 million in 2025.
  • Its last three reported values are $193.1 million in Q3 2025, $206.8 million for Q2 2025, and $222.4 million during Q1 2025.